A new era of targeting the ancient gatekeepers of the immune system: Toll-like agonists in the treatment of allergic rhinitis and asthma

International Archives of Allergy and Immunology

Volumn 164, Issue 1, 2014, Pages 46-63

  Aryan, Zahra ^a   Holgate, Stephen T ^c   Radzioch, Danuta ^e   Rezaei, Nima ^a,b,d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

Adjuvants; Allergic rhinitis; Asthma; CD14; CpG oligodeoxynucleotide; Hygiene hypothesis; Immunostimulatory sequence oligonucleotides; Immunotherapy; Innate immunity; Toll like receptors

Indexed keywords

ADJUVANT; AZD 8848; CAPSAZEPINOID; CPG OLIGODEOXYNUCLEOTIDE; ERITORAN; GSK 2245035; IMIQUIMOD; MACROPHAGE ACTIVATING LIPOPEPTIDE 2; MPL; PATTERN RECOGNITION RECEPTOR; PHOSPHORYL LIPID A; POLLINEX QUATTRO; QBG 10; RESIQUIMOD; RESVERATROL; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; VACCINE; VTX 1463; ALLERGY VACCINE; BACTERIAL DNA; CAPSAZEPINE; CD14 ANTIGEN; DOUBLE STRANDED RNA; IMIDAZOQUINOLINE DERIVATIVE; LIPOPROTEIN; LIPOPROTEIN 1; MOTOLIMOD; OLIGONUCLEOTIDE; SINGLE STRANDED DNA; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 8; VIRUS RNA;

ALLERGIC RHINITIS; ASTHMA; DRUG ACTIVITY; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN TARGETING; PRURITUS; RESPIRATORY TRACT ALLERGY; REVIEW; SKIN REDNESS; SUBCUTANEOUS IMMUNOTHERAPY; SWELLING; ALLERGIC ASTHMA; CELL SURFACE; CLINICAL TRIAL (TOPIC); GENE TARGETING; IMMUNE SYSTEM; IMMUNOTHERAPY; META ANALYSIS (TOPIC); MONOTHERAPY; MULTICENTER STUDY (TOPIC); PHARMACEUTICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC);

ANIMALS; ANTI-ALLERGIC AGENTS; ASTHMA; HUMANS; RHINITIS, ALLERGIC, PERENNIAL; TOLL-LIKE RECEPTORS;

EID: 84900876706     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000362553     Document Type: Review

References (140)

1. Hollams EM, Deverell M, Serralha M, Suriyaarachchi D, Parsons F, Zhang G, de Klerk N, Holt BJ, Ladyman C, Sadowska A, Rowe J, Loh R, Sly PD, Holt PG: Elucidation of asthma phenotypes in atopic teenagers through parallel immunophenotypic and clinical profiling. J Allergy Clin Immunol 2009; 124: 463-470.e416.
2. Bousquet J, Schunemann HJ, Samolinski B, et al: Allergic Rhinitis and Its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol 2012; 130: 1049-1062.
3. Holt PG, Upham JW, Sly PD: Contemporaneous maturation of immunologic and respiratory functions during early childhood: implications for development of asthma prevention strategies. J Allergy Clin Immunol 2005; 116: 16-25.
4. Ramaprakash H, Hogaboam CM: Intranasal CpG therapy attenuated experimental fungal asthma in a TLR9-dependent and independent manner. Int Arch Allergy Immunol 2010; 152: 98-112.
5. Song DJ, Min MG, Miller M, Cho JY, Yum HY, Broide DH: Toll-like receptor-9 agonist inhibits airway inflammation, remodeling and hyperreactivity in mice exposed to chronic environmental tobacco smoke and allergen. Int Arch Allergy Immunol 2010; 151: 285-296.
6. Hedayat M, Takeda K, Rezaei N: Prophylactic and therapeutic implications of toll-like receptor ligands. Med Res Rev 2012; 32: 294-325.
7. Holt PG, Sly PD: Interaction between adaptive and innate immune pathways in the pathogenesis of atopic asthma: operation of a lung/bone marrow axis. Chest 2011; 139: 1165-1171.
8. Homma T, Matsukura S, Hirose T, Ohnishi T, Kimura T, Kurokawa M, Ieki K, Odaka M, Suzuki S, Watanabe S, Sato M, Kawaguchi M, Schleimer RP, Adachi M: Cooperative activation of CCL5 expression by TLR3 and tumor necrosis factor- or interferon- through nuclear factor-B or STAT-1 in airway epithelial cells. Int Arch Allergy Immunol 2010; 152(suppl 1):9-17.
9. Kasakura K, Takahashi K, Aizawa T, Hosono A, Kaminogawa S: A TLR2 ligand suppresses allergic inflammatory reactions by acting directly on mast cells. Int Arch Allergy Immunol 2009; 150: 359-369.
10. Kucuksezer UC, Palomares O, Ruckert B, Jartti T, Puhakka T, Nandy A, Gemicioglu B, Fahrner HB, Jung A, Deniz G, Akdis CA, Akdis M: Triggering of specific toll-like receptors and proinflammatory cytokines breaks allergen-specific T cell tolerance in human tonsils and peripheral blood. J Allergy Clin Immunol 2013; 131: 875-885.
11. Hammad H, Chieppa M, Perros F, Willart MA, Germain RN, Lambrecht BN: House dust mite allergen induces asthma via toll-like receptor triggering of airway structural cells. Nat Med 2009; 15: 410-416.
12. Li DQ, Zhang L, Pflugfelder SC, De Paiva CS, Zhang X, Zhao G, Zheng X, Su Z, Qu Y: Short ragweed pollen triggers allergic inflammation through Toll-like receptor 4-dependent thymic stromal lymphopoietin/OX40 ligand/OX40 signaling pathways. J Allergy Clin Immunol 2011; 128: 1318-1325.e2.
13. Romagnani S: Coming back to a missing immune deviation as the main explanatory mechanism for the hygiene hypothesis. J Allergy Clin Immunol 2007; 119: 1511-1513.
14. Loss G, Bitter S, Wohlgensinger J, Frei R, Roduit C, Genuneit J, Pekkanen J, Roponen M, Hirvonen MR, Dalphin JC, Dalphin ML, Riedler J, von Mutius E, Weber J, Kabesch M, Michel S, Braun-Fahrlander C, Lauener R: Prenatal and early-life exposures alter expression of innate immunity genes: the PASTURE cohort study. J Allergy Clin Immunol 2012; 130: 523-530.e529.
15. Sly PD, Boner AL, Bjorksten B, Bush A, Custovic A, Eigenmann PA, Gern JE, Gerritsen J, Hamelmann E, Helms PJ, Lemanske RF, Martinez F, Pedersen S, Renz H, Sampson H, von Mutius E, Wahn U, Holt PG: Early identification of atopy in the prediction of persistent asthma in children. Lancet 2008; 372: 1100-1106.
16. Wada K, Kobayashi T, Matsuwaki Y, Moriyama H, Kita H: Alternaria inhibits doublestranded RNA-induced cytokine production through Toll-like receptor 3. Int Arch Allergy Immunol 2013; 161(suppl 2):75-83.
17. Wilson RH, Maruoka S, Whitehead GS, Foley JF, Flake GP, Sever ML, Zeldin DC, Kraft M, Garantziotis S, Nakano H, Cook DN: The tolllike receptor 5 ligand flagellin promotes asthma by priming allergic responses to indoor allergens. Nat Med 2012; 18: 1705-1710.
18. Page K, Ledford JR, Zhou P, Wills-Karp M: A TLR2 agonist in German cockroach frass activates MMP-9 release and is protective against allergic inflammation in mice. J Immunol 2009; 183: 3400-3408.
19. Yang H, Kong X, Wei J, Liu C, Song W, Zhang W, Wei W, He S: Cockroach allergen Per a 7 down-regulates expression of Toll-like receptor 9 and IL-12 release from P815 cells through PI3k and MAPK signaling pathways. Cell Physiol Biochem 2012; 29: 561-570.
20. Bauer RN, Diaz-Sanchez D, Jaspers I: Effects of air pollutants on innate immunity: the role of toll-like receptors and nucleotide-binding oligomerization domain-like receptors. J Allergy Clin Immunol 2012; 129: 14-26.
21. Kim TB, Kim SY, Moon KA, Park CS, Jang MK, Yun ES, Cho YS, Moon HB, Lee KY: Five-aminoimidazole-4-carboxamide-1-4-ribofuranoside attenuates poly (i:C)-induced airway inflammation in a murine model of asthma. Clin Exp Allergy 2007; 37: 1709-1719.
22. Mushaben EM, Brandt EB, Hershey GK, Le Cras TD: Differential effects of rapamycin and dexamethasone in mouse models of established allergic asthma. PLoS One 2013; 8:e54426.
23. Yang J, Li Q, Zhou XD, Kolosov VP, Perelman JM: Naringenin attenuates mucous hypersecretion by modulating reactive oxygen species production and inhibiting NF-B activity via EGFR-PI3K-Akt/ERK MAPKinase signaling in human airway epithelial cells. Mol Cell Biochem 2011; 351: 29-40.
24. Zang N, Xie X, Deng Y, Wu S, Wang L, Peng C, Li S, Ni K, Luo Y, Liu E: Resveratrol-mediated gamma interferon reduction prevents airway inflammation and airway hyperresponsiveness in respiratory syncytial virusinfected immunocompromised mice. J Virol 2011; 85: 13061-13068.
25. Aumeunier A, Grela F, Ramadan A, Pham Van L, Bardel E, Gomez Alcala A, Jeannin P, Akira S, Bach JF, Thieblemont N: Systemic Toll-like receptor stimulation suppresses experimental allergic asthma and autoimmune diabetes in NOD mice. PLoS One 2010; 5: e11484.
26. Ly NP, Litonjua A, Gold DR, Celedon JC: Gut microbiota, probiotics, and vitamin D: interrelated exposures influencing allergy, asthma, and obesity? J Allergy Clin Immunol 2011; 127: 1087-1096.
27. Toki S, Kagaya S, Shinohara M, Wakiguchi H, Matsumoto T, Takahata Y, Morimatsu F, Saito H, Matsumoto K: Lactobacillus rhamnosus GG and Lactobacillus casei suppress Escherichia coli-induced chemokine expression in intestinal epithelial cells. Int Arch Allergy Immunol 2009; 148: 45-58.
28. Olivier A, Sainz-Perez A, Dong H, Sparwasser T, Majlessi L, Leclerc C: The adjuvant effect of TLR agonists on CD4 + effector T cells is under the indirect control of regulatory T cells. Eur J Immunol 2011; 41: 2303-2313.
29. Ekman AK, Virtala R, Fransson M, Adner M, Benson M, Jansson L, Cardell LO: Systemic up-regulation of TLR4 causes lipopolysaccharide-induced augmentation of nasal cytokine release in allergic rhinitis. Int Arch Allergy Immunol 2012; 159: 6-14.
30. Lee WI, Yao TC, Yeh KW, Chen LC, Ou LS, Huang JL: Stronger Toll-like receptor 1/2, 4, and 7/8 but less responses in peripheral blood mononuclear cells in non-infectious exacerbated asthmatic children. Immunobiology 2013; 218: 192-200.
31. Tversky JR, Le TV, Bieneman AP, Chichester KL, Hamilton RG, Schroeder JT: Human blood dendritic cells from allergic subjects have impaired capacity to produce interferon- via Toll-like receptor 9. Clin Exp Allergy 2008; 38: 781-788.
32. Mansson A, Cardell LO: Role of atopic status in Toll-like receptor (TLR)7-and TLR9-mediated activation of human eosinophils. J Leukoc Biol 2009; 85: 719-727.
33. von Bubnoff D, Sell U, Arriens S, Specht S, Hoerauf A, Bieber T: Differential expression of Toll-like receptor 2 on dendritic cells from asymptomatic and symptomatic atopic donors. Int Arch Allergy Immunol 2012; 159: 41-50.
34. Yeganeh M, Henneke P, Rezaei N, Ehl S, Thiel D, Matamoros N, Pietrogrande C, Espanol T, Litzman J, Franco JL, Sanal O, Kilic SS, Breborowicz A, Plebani A, Renner E, Rothenfusser S, Hawn TR, Woellner C, Grimbacher B: Tolllike receptor stimulation induces higher TNF- secretion in peripheral blood mononuclear cells from patients with hyper IgE syndrome. Int Arch Allergy Immunol 2008; 146: 190-194.
35. Tversky JR, Bieneman AP, Chichester KL, Hamilton RG, Schroeder JT: Subcutaneous allergen immunotherapy restores human dendritic cell innate immune function. Clin Exp Allergy 2010; 40: 94-102.
36. Hiraguchi Y, Tanida H, Hosoki K, Nagao M, Tokuda R, Fujisawa T: Inhibition of eosinophil activation mediated by a Toll-like receptor 7 ligand with a combination of procaterol and budesonide. Int Arch Allergy Immunol 2011; 155(suppl 1):85-89.
37. Vandenbulcke L, Bachert C, Van Cauwenberge P, Claeys S: The innate immune system and its role in allergic disorders. Int Arch Allergy Immunol 2006; 139: 159-165.
38. Groskreutz DJ, Monick MM, Powers LS, Yarovinsky TO, Look DC, Hunninghake GW: Respiratory syncytial virus induces TLR3 protein and protein kinase R, leading to increased double-stranded RNA responsiveness in airway epithelial cells. J Immunol 2006; 176: 1733-1740.
39. Xie XH, Law HK, Wang LJ, Li X, Yang XQ, Liu EM: Lipopolysaccharide induces IL-6 production in respiratory syncytial virus-infected airway epithelial cells through the Tolllike receptor 4 signaling pathway. Pediatr Res 2009; 65: 156-162.
40. Valkov E, Stamp A, Dimaio F, Baker D, Verstak B, Roversi P, Kellie S, Sweet MJ, Mansell A, Gay NJ, Martin JL, Kobe B: Crystal structure of Toll-like receptor adaptor MAL/TIRAP reveals the molecular basis for signal transduction and disease protection. Proc Natl Acad Sci USA 2011; 108: 14879-14884.
41. Lee IT, Lee CW, Tung WH, Wang SW, Lin CC, Shu JC, Yang CM: Cooperation of TLR2 with MyD88, PI3K, and Rac1 in lipoteichoic acid-induced cPLA2/COX-2-dependent airway inflammatory responses. Am J Pathol 2010; 176: 1671-1684.
42. Wong CK, Cheung PF, Ip WK, Lam CW: Intracellular signaling mechanisms regulating Toll-like receptor-mediated activation of eosinophils. Am J Respir Cell Mol Biol 2007; 37: 85-96.
43. Chiou YL, Lin CY: Der p2 activates airway smooth muscle cells in a TLR2/MyD88-dependent manner to induce an inflammatory response. J Cell Physiol 2009; 220: 311-318.
44. Melkamu T, Squillace D, Kita H, O'Grady SM: Regulation of TLR2 expression and function in human airway epithelial cells. J Membr Biol 2009; 229: 101-113.
45. Redecke V, Hacker H, Datta SK, Fermin A, Pitha PM, Broide DH, Raz E: Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma. J Immunol 2004; 172: 2739-2743.
46. Patel M, Xu D, Kewin P, Choo-Kang B, Mc-Sharry C, Thomson NC, Liew FY: TLR2 agonist ameliorates established allergic airway inflammation by promoting Th1 response and not via regulatory T cells. J Immunol 2005; 174: 7558-7563.
47. Zhou C, Kang XD, Chen Z: A synthetic Tolllike receptor 2 ligand decreases allergic immune responses in a mouse rhinitis model sensitized to mite allergen. J Zhejiang Univ Sci B 2008; 9: 279-285.
48. Velasco G, Campo M, Manrique OJ, Bellou A, He H, Arestides RS, Schaub B, Perkins DL, Finn PW: Toll-like receptor 4 or 2 agonists decrease allergic inflammation. Am J Respir Cell Mol Biol 2005; 32: 218-224.
49. Tsai YG, Yang KD, Niu DM, Chien JW, Lin CY: TLR2 agonists enhance CD8 + Foxp3 + regulatory T cells and suppress Th2 immune responses during allergen immunotherapy. J Immunol 2010; 184: 7229-7237.
50. Taylor RC, Richmond P, Upham JW: Tolllike receptor 2 ligands inhibit Th2 responses to mite allergen. J Allergy Clin Immunol 2006; 117: 1148-1154.
51. Weigt H, Muhlradt PF, Emmendorffer A, Krug N, Braun A: Synthetic mycoplasma-derived lipopeptide MALP-2 induces maturation and function of dendritic cells. Immunobiology 2003; 207: 223-233.
52. Borsutzky S, Kretschmer K, Becker PD, Muhlradt PF, Kirschning CJ, Weiss S, Guzman CA: The mucosal adjuvant macrophage-activating lipopeptide-2 directly stimulates B lymphocytes via the TLR2 without the need of accessory cells. J Immunol 2005; 174: 6308-6313.
53. Weigt H, Muhlradt PF, Larbig M, Krug N, Braun A: The Toll-like receptor-2/6 agonist macrophage-activating lipopeptide-2 cooperates with IFN- to reverse the Th2 skew in an in vitro allergy model. J Immunol 2004; 172: 6080-6086.
54. Weigt H, Nassenstein C, Tschernig T, Muhlradt PF, Krug N, Braun A: Efficacy of macrophage-activating lipopeptide-2 combined with interferon- in a murine asthma model. Am J Respir Crit Care Med 2005; 172: 566-572.
55. Pabst R, Durak D, Roos A, Luhrmann A, Tschernig T: TLR2/6 stimulation of the rat lung: effects on lymphocyte subsets, natural killer cells and dendritic cells in different parts of the air-conducting compartments and at different ages. Immunology 2009; 126: 132-139.
56. Fuchs B, Knothe S, Rochlitzer S, Nassimi M, Greweling M, Lauenstein HD, Nassenstein C, Muller M, Ebensen T, Dittrich AM, Krug N, Guzman CA, Braun A: A toll-like receptor 2/6 agonist reduces allergic airway inflammation in chronic respiratory sensitisation to timothy grass pollen antigens. Int Arch Allergy Immunol 2010; 152: 131-139.
57. Switalla S, Lauenstein L, Prenzler F, Knothe S, Forster C, Fieguth HG, Pfennig O, Schaumann F, Martin C, Guzman CA, Ebensen T, Muller M, Hohlfeld JM, Krug N, Braun A, Sewald K: Natural innate cytokine response to immunomodulators and adjuvants in human precision-cut lung slices. Toxicol Appl Pharmacol 2010; 246: 107-115.
58. Prajeeth CK, Jirmo AC, Krishnaswamy JK, Ebensen T, Guzman CA, Weiss S, Constabel H, Schmidt RE, Behrens GM: The synthetic TLR2 agonist BPPcysMPEG leads to efficient cross-priming against co-administered and linked antigens. Eur J Immunol 2010; 40: 1272-1283.
59. Knothe S, Mutschler V, Rochlitzer S, Winkler C, Ebensen T, Guzman CA, Hohlfeld J, Braun A, Muller M: Local treatment with BPPcysMPEG reduces allergic airway inflammation in sensitized mice. Immunobiology 2011; 216: 110-117.
60. Revets H, Pynaert G, Grooten J, De Baetselier P: Lipoprotein I, a TLR2/4 ligand modulates Th2-driven allergic immune responses. J Immunol 2005; 174: 1097-1103.
61. Akdis CA, Kussebi F, Pulendran B, Akdis M, Lauener RP, Schmidt-Weber CB, Klunker S, Isitmangil G, Hansjee N, Wynn TA, Dillon S, Erb P, Baschang G, Blaser K, Alkan SS: Inhibition of T helper 2-type responses, IgE production and eosinophilia by synthetic lipopeptides. Eur J Immunol 2003; 33: 2717-2726.
62. Rosewich M, Schulze J, Fischer von Weikersthal-Drachenberg KJ, Zielen S: Ultra-short course immunotherapy in children and adolescents during a 3-yrs post-marketing surveillance study. Pediatr Allergy Immunol 2010; 21:e185-e189.
63. Scichilone N, Minaldi C, Santagata R, Battaglia S, Camarda G, Bellia V: Anti-inflammatory effects of pre-seasonal Th1-adjuvant vaccine to parietaria judaica in asthmatics. J Asthma Allergy 2011; 4: 19-25.
64. Musarra A, Bignardi D, Troise C, Passalacqua G: Long-lasting effect of a monophosphoryl lipid-adjuvanted immunotherapy to parietaria: a controlled field study. Eur Ann Allergy Clin Immunol 2010; 42: 115-119.
65. von Baehr V, Hermes A, von Baehr R, Scherf HP, Volk HD, Fischer von Weikersthal-Drachenberg KJ, Woroniecki S: Allergoidspecific T-cell reaction as a measure of the immunological response to specific immunotherapy (SIT) with a Th1-adjuvanted allergy vaccine. J Investig Allergol Clin Immunol 2005; 15: 234-241.
66. Rosewich M, Schulze J, Eickmeier O, Telles T, Rose MA, Schubert R, Zielen S: Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid a in children. Clin Exp Immunol 2010; 160: 403-410.
67. Baldrick P, Richardson D, Woroniecki SR, Lees B: Pollinex Quattro Ragweed: safety evaluation of a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPL) for the treatment of ragweed pollen allergy. J Appl Toxicol 2007; 27: 399-409.
68. Baldrick P, Richardson D, Wheeler AW: Safety evaluation of a glutaraldehyde modified tyrosine adsorbed housedust mite extract containing monophosphoryl lipid A (MPL) adjuvant: a new allergy vaccine for dust mite allergy. Vaccine 2001; 20: 737-743.
69. Casale TB, Kessler J, Romero FA: Safety of the intranasal Toll-like receptor4 agonist CRX-675 in allergic rhinitis. Ann Allergy Asthma Immunol 2006; 97: 454-456.
70. Lee K, Kim SH, Yoon HJ, Paik DJ, Kim JM, Youn J: Bacillus-derived poly-glutamic acid attenuates allergic airway inflammation through a Toll-like receptor-4-dependent pathway in a murine model of asthma. Clin Exp Allergy 2011; 41: 1143-1156.
71. Bortolatto J, Borducchi E, Rodriguez D, Keller AC, Faquim-Mauro E, Bortoluci KR, Mucida D, Gomes E, Christ A, Schnyder-Candrian S, Schnyder B, Ryffel B, Russo M: Toll-like receptor 4 agonists adsorbed to aluminium hydroxide adjuvant attenuate ovalbumin-specific allergic airway disease: role of MyD88 adaptor molecule and interleukin-12/interferon- axis. Clin Exp Allergy 2008; 38: 1668-1679.
72. Matsushita H, Ohta S, Shiraishi H, Suzuki S, Arima K, Toda S, Tanaka H, Nagai H, Kimoto M, Inokuchi A, Izuhara K: Endotoxin tolerance attenuates airway allergic inflammation in model mice by suppression of the T-cell stimulatory effect of dendritic cells. Int Immunol 2010; 22: 739-747.
73. Savov JD, Brass DM, Lawson BL, McElvania-Tekippe E, Walker JK, Schwartz DA: Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide. Am J Physiol Lung Cell Mol Physiol 2005; 289:L329-L337.
74. Peake HL, Prosser AC, Thompson PJ: Expression of Toll-like receptors on neutrophils and eosinophils isolated from individuals with and without asthma. J Allergy Clin Immunol 2006; 117:S14.
75. Raoust E, Balloy V, Garcia-Verdugo I, Touqui L, Ramphal R, Chignard M: Pseudomonas aeruginosa LPS or flagellin are sufficient to activate TLR-dependent signaling in murine alveolar macrophages and airway epithelial cells. PLoS One 2009; 4:e7259.
76. Sukkar MB, Xie S, Khorasani NM, Kon OM, Stanbridge R, Issa R, Chung KF: Toll-like receptor 2, 3, and 4 expression and function in human airway smooth muscle. J Allergy Clin Immunol 2006; 118: 641-648.
77. Lun SW, Wong CK, Ko FW, Hui DS, Lam CW: Expression and functional analysis of Toll-like receptors of peripheral blood cells in asthmatic patients: implication for immunopathological mechanism in asthma. J Clin Immunol 2009; 29: 330-342.
78. Honko AN, Sriranganathan N, Lees CJ, Mizel SB: Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis . Infect Immun 2006; 74: 1113-1120.
79. Nguyen CT, Kim SY, Kim MS, Lee SE, Rhee JH: Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice. Vaccine 2011; 29: 5731-5739.
80. Hong SH, Byun YH, Nguyen CT, Kim SY, Seong BL, Park S, Woo GJ, Yoon Y, Koh JT, Fujihashi K, Rhee JH, Lee SE: Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection. Vaccine 2012; 30: 466-474.
81. Lee SE, Koh YI, Kim MK, Kim YR, Kim SY, Nam JH, Choi YD, Bae SJ, Ko YJ, Ryu HJ, Koh JT, Choy HE, Rhee JH: Inhibition of airway allergic disease by co-administration of flagellin with allergen. J Clin Immunol 2008; 28: 157-165.
82. Schülke S, Waibler Z, Mende M-S, Zoccatelli G, Vieths S, Toda M, Scheurer S: Fusion protein of TLR5-ligand and allergen potentiates activation and IL-10 secretion in murine myeloid DC. Mol Immunol 2010; 48: 341-350.
83. Bacharier LB, Phillips BR, Bloomberg GR, Zeiger RS, Paul IM, Krawiec M, Guilbert T, Chinchilli VM, Strunk RC: Severe intermittent wheezing in preschool children: a distinct phenotype. J Allergy Clin Immunol 2007; 119: 604-610.
84. Shiraishi Y, Asano K, Niimi K, Fukunaga K, Wakaki M, Kagyo J, Takihara T, Ueda S, Nakajima T, Oguma T, Suzuki Y, Shiomi T, Sayama K, Kagawa S, Ikeda E, Hirai H, Nagata K, Nakamura M, Miyasho T, Ishizaka A: Cyclooxygenase-2/ prostaglandin D2/CRTH2 pathway mediates double-stranded RNA-induced enhancement of allergic airway inflammation. J Immunol 2008; 180: 541-549.
85. Uller L, Leino M, Bedke N, Sammut D, Green B, Lau L, Howarth PH, Holgate ST, Davies DE: Double-stranded RNA induces disproportionate expression of thymic stromal lymphopoietin versus interferon-? in bronchial epithelial cells from donors with asthma. Thorax 2010; 65: 626-632.
86. Starkhammar M, Kumlien Georen S, Swedin L, Dahlen SE, Adner M, Cardell LO: Intranasal administration of poly(I:C) and LPS in BALB/c mice induces airway hyperresponsiveness and inflammation via different pathways. PLoS One 2012; 7:e32110.
87. Morishima H, Kajiwara K, Akiyama K, Yanagihara Y: Ligation of Toll-like receptor 3 differentially regulates M2 and M3 muscarinic receptor expression and function in human airway smooth muscle cells. Int Arch Allergy Immunol 2008; 145: 163-174.
88. Choi JP, Kim YS, Kim OY, Kim YM, Jeon SG, Roh TY, Park JS, Gho YS, Kim YK: TNF- is a key mediator in the development of Th2 cell response to inhaled allergens induced by a viral PAMP double-stranded RNA. Allergy 2012; 67: 1138-1148.
89. Sel S, Wegmann M, Bauer S, Garn H, Alber G, Renz H: Immunomodulatory effects of viral TLR ligands on experimental asthma depend on the additive effects of IL-12 and IL-10. J Immunol 2007; 178: 7805-7813.
90. Mahmutovic-Persson I, Johansson M, Brandelius A, Calven J, Bjermer L, Yudina Y, Uller L: Capacity of capsazepinoids to relax human small airways and inhibit TLR3-induced TSLP and IFN? production in diseased bronchial epithelial cells. Int Immunopharmacol 2012; 13: 292-300.
91. Skold AE, Hasan M, Vargas L, Saidi H, Bosquet N, Le Grand R, Smith CI, Spetz AL: Single-stranded DNA oligonucleotides inhibit TLR3-mediated responses in human monocyte-derived dendritic cells and in vivo in cynomolgus macaques. Blood 2012; 120: 768-777.
92. Kaufman EH, Fryer AD, Jacoby DB: Tolllike receptor 7 agonists are potent and rapid bronchodilators in guinea pigs. J Allergy Clin Immunol 2011; 127: 462-469.
93. Lan T, Bhagat L, Wang D, Dai M, Kandimalla ER, Agrawal S: Synthetic oligoribonucleotides containing arabinonucleotides act as agonists of TLR7 and 8. Bioorg Med Chem Lett 2009; 19: 2044-2047.
94. Gunzer M, Riemann H, Basoglu Y, Hillmer A, Weishaupt C, Balkow S, Benninghoff B, Ernst B, Steinert M, Scholzen T, Sunderkotter C, Grabbe S: Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion. Blood 2005; 106: 2424-2432.
95. Baenziger S, Heikenwalder M, Johansen P, Schlaepfer E, Hofer U, Miller RC, Diemand S, Honda K, Kundig TM, Aguzzi A, Speck RF: Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology. Blood 2009; 113: 377-388.
96. Xirakia C, Koltsida O, Stavropoulos A, Thanassopoulou A, Aidinis V, Sideras P, Andreakos E: Toll-like receptor 7-triggered immune response in the lung mediates acute and long-lasting suppression of experimental asthma. Am J Respir Crit Care Med 2010; 181: 1207-1216.
97. Hackstein H, Hagel N, Knoche A, Kranz S, Lohmeyer J, von Wulffen W, Kershaw O, Gruber AD, Bein G, Baal N: Skin TLR7 triggering promotes accumulation of respiratory dendritic cells and natural killer cells. PLoS One 2012; 7:e43320.
98. Ekman AK, Adner M, Cardell LO: Toll-like receptor 7 activation reduces the contractile response of airway smooth muscle. Eur J Pharmacol 2011; 652: 145-151.
99. Stokes JR, Sorkness RL, Kaplan MR, Castleman WL, Tomai MA, Miller RL, Lemanske RF Jr: Attenuation of virus-induced airway dysfunction in rats treated with imiquimod. Eur Respir J 1998; 11: 324-329.
100. Camateros P, Tamaoka M, Hassan M, Marino R, Moisan J, Marion D, Guiot MC, Martin JG, Radzioch D: Chronic asthmainduced airway remodeling is prevented by Toll-like receptor-7/8 ligand s28463. Am J Respir Crit Care Med 2007; 175: 1241-1249.
101. Moisan J, Camateros P, Thuraisingam T, Marion D, Koohsari H, Martin P, Boghdady ML, Ding A, Gaestel M, Guiot MC, Martin JG, Radzioch D: TLR7 ligand prevents allergen-induced airway hyperresponsiveness and eosinophilia in allergic asthma by a MYD88-dependent and MK2-independent pathway. Am J Physiol Lung Cell Mol Physiol 2006; 290:L987-L995.
102. Duechs MJ, Hahn C, Benediktus E, Werner-Klein M, Braun A, Hoymann HG, Gantner F, Erb KJ: TLR agonist mediated suppression of allergic responses is associated with increased innate inflammation in the airways. Pulm Pharmacol Ther 2011; 24: 203-214.
103. Quarcoo D, Weixler S, Joachim RA, Stock P, Kallinich T, Ahrens B, Hamelmann E: Resiquimod, a new immune response modifier from the family of imidazoquinolinamines, inhibits allergen-induced Th2 responses, airway inflammation and airway hyper-reactivity in mice. Clin Exp Allergy 2004; 34: 1314-1320.
104. Grela F, Aumeunier A, Bardel E, Van LP, Bourgeois E, Vanoirbeek J, Leite-de-Moraes M, Schneider E, Dy M, Herbelin A, Thieblemont N: The TLR7 agonist R848 alleviates allergic inflammation by targeting invariant NKT cells to produce IFN-. J Immunol 2011; 186: 284-290.
105. Vultaggio A, Nencini F, Pratesi S, Maggi L, Guarna A, Annunziato F, Romagnani S, Parronchi P, Maggi E: The TLR7 ligand 9-benzyl-2-butoxy-8-hydroxy adenine inhibits IL-17 response by eliciting IL-10 and IL-10-inducing cytokines. J Immunol 2011; 186: 4707-4715.
106. Greiff L, Cervin A, Ahlstrom-Emanuelsson C, Almqvist G, Andersson M, Dolata J, Eriksson L, Hogestatt E, Kallen A, Norlen P, Sjolin IL, Widegren H: Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis. Respir Res 2012; 13: 53.
107. Horak F, Zieglmayer P, Zieglmayer R, Lemell P, Newkirk M, Manjarrez K, Randall TD, Hershberg R: Intranasal Tolllike receptor agonist (vtx-1463) significantly improves symptoms of allergic rhinitis in a randomized, placebo-controlled trial. J Allergy Clin Immunol 2011; 127: AB199.
108. Horak F: VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis. Expert Opin Investig Drugs 2011; 20: 981-986.
109. Kline JN, Waldschmidt TJ, Businga TR, Lemish JE, Weinstock JV, Thorne PS, Krieg AM: Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol 1998; 160: 2555-2559.
110. Kim HK, Lee CH, Kim JM, Ayush O, Im SY, Lee HK: Biphasic late airway hyperresponsiveness in a murine model of asthma. Int Arch Allergy Immunol 2012; 160: 173-183.
111. Zhang BY, Chi S, Sun Y: Modulation of Toll-like signal path of allergic asthma by CpG-ODNs from Bordetella pertussis (in Chinese). Yao Xue Xue Bao 2011; 46: 285-292.
112. Luhrmann A, Tschernig T, von der Leyen H, Hecker M, Pabst R, Wagner AH: Decoy oligodeoxynucleotide against STAT transcription factors decreases allergic inflammation in a rat asthma model. Exp Lung Res 2010; 36: 85-93.
113. Jain VV, Kitagaki K, Businga T, Hussain I, George C, O'Shaughnessy P, Kline JN: CpGoligodeoxynucleotides inhibit airway remodeling in a murine model of chronic asthma. J Allergy Clin Immunol 2002; 110: 867-872.
114. Lee SY, Cho JY, Miller M, McElwain K, McElwain S, Sriramarao P, Raz E, Broide DH: Immunostimulatory DNA inhibits allergen-induced peribronchial angiogenesis in mice. J Allergy Clin Immunol 2006; 117: 597-603.
115. Santeliz JV, Van Nest G, Traquina P, Larsen E, Wills-Karp M: Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J Allergy Clin Immunol 2002; 109: 455-462.
116. Chiang DJ, Ye YL, Chen WL, Lee YL, Hsu NY, Chiang BL: Ribavirin or CpG DNA sequence-modulated dendritic cells decrease the IgE level and airway inflammation. Am J Respir Crit Care Med 2003; 168: 575-580.
117. Banerjee B, Kelly KJ, Fink JN, Henderson JD Jr, Bansal NK, Kurup VP: Modulation of airway inflammation by immunostimulatory CpG oligodeoxynucleotides in a murine model of allergic aspergillosis. Infect Immun 2004; 72: 6087-6094.
118. Ashino S, Wakita D, Zhang Y, Chamoto K, Kitamura H, Nishimura T: CpG-ODN inhibits airway inflammation at effector phase through down-regulation of antigen-specific Th2-cell migration into lung. Int Immunol 2008; 20: 259-266.
119. Fedulov A, Silverman E, Xiang Y, Leme A, Kobzik L: Immunostimulatory CpG oligonucleotides abrogate allergic susceptibility in a murine model of maternal asthma transmission. J Immunol 2005; 175: 4292-4300.
120. Serebrisky D, Teper AA, Huang CK, Lee SY, Zhang TF, Schofield BH, Kattan M, Sampson HA, Li XM: CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma. J Immunol 2000; 165: 5906-5912.
121. Kline JN, Kitagaki K, Businga TR, Jain VV: Treatment of established asthma in a murine model using CpG oligodeoxynucleotides. Am J Physiol Lung Cell Mol Physiol 2002; 283:L170-L179.
122. Hussain I, Jain VV, Kitagaki K, Businga TR, O'Shaughnessy P, Kline JN: Modulation of murine allergic rhinosinusitis by CpG oligodeoxynucleotides. Laryngoscope 2002; 112: 1819-1826.
123. Rhee CS, Libet L, Chisholm D, Takabayashi K, Baird S, Bigby TD, Lee CH, Horner AA, Raz E: Allergen-independent immunostimulatory sequence oligodeoxynucleotide therapy attenuates experimental allergic rhinitis. Immunology 2004; 113: 106-113.
124. Trujillo-Vargas CM, Ramirez-Pineda JR, Palmetshofer A, Grunewald S, Moll H, Berberich C, Erb KJ: Mice vaccinated with allergen-pulsed myeloid dendritic cells are not protected from developing allergen-induced Th2 responses. Int Arch Allergy Immunol 2005; 137: 219-228.
125. Kapoor S, Geng L, Feldman A, Jyonouchi H: Characterization of severe asthma (SA) in children of inner-city of Newark: altered responses to recall antigens and a panel of agonists of Toll-like receptors (TLR). J Allergy Clin Immunol 2011; 127:AB61.
126. Asai K, Foley SC, Sumi Y, Yamauchi Y, Takeda N, Desrosiers M, Lavigne F, Hamid Q: Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy increases CD4 + CD25 + T cells in the nasal mucosa of subjects with allergic rhinitis. Allergol Int 2008; 57: 377-381.
127. Creticos PS, Schroeder JT, Hamilton RG, Balcer-Whaley SL, Khattignavong AP, Lindblad R, Li H, Coffman R, Seyfert V, Eiden JJ, Broide D: Immunotherapy with a ragweed-Toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006; 355: 1445-1455.
128. Simons FE, Shikishima Y, Van Nest G, Eiden JJ, HayGlass KT: Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol 2004; 113: 1144-1151.
129. Tulic MK, Fiset PO, Christodoulopoulos P, Vaillancourt P, Desrosiers M, Lavigne F, Eiden J, Hamid Q: Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol 2004; 113: 235-241.
130. Nayak AS, Tripathy I, Levitt D: Novel Amb a 1 CpG oligodeoxyribonucleotide conjugate ragweed vaccine administered to children. J Allergy Clin Immunol 2006; 117: S159.
131. Gauvreau GM, Hessel EM, Boulet LP, Coffman RL, O'Byrne PM: Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway responses. Am J Respir Crit Care Med 2006; 174: 15-20.
132. Klimek L, Willers J, Hammann-Haenni A, Pfaar O, Stocker H, Mueller P, Renner WA, Bachmann MF: Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. Clin Exp Allergy 2011; 41: 1305-1312.
133. Senti G, Johansen P, Haug S, Bull C, Gottschaller C, Muller P, Pfister T, Maurer P, Bachmann MF, Graf N, Kundig TM: Use of a-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy 2009; 39: 562-570.
134. Connolly DJ, O'Neill LA: New developments in Toll-like receptor targeted therapeutics. Curr Opin Pharmacol 2012; 12: 510-518.
135. DuBuske LM, Frew AJ, Horak F, Keith PK, Corrigan CJ, Aberer W, Holdich T, von Weikersthal-Drachenberg KJ: Ultrashortspecific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy Asthma Proc 2011; 32: 239-247.
136. Pfaar O, Barth C, Jaschke C, Hormann K, Klimek L: Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a phase I/IIa study. Int Arch Allergy Immunol 2011; 154: 336-344.
137. Drachenberg KJ, Heinzkill M, Urban E, Woroniecki SR: Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid a (MPL) for children and adolescents. Allergol Immunopathol (Madr) 2003; 31: 270-277.
138. Mothes N, Heinzkill M, Drachenberg KJ, Sperr WR, Krauth MT, Majlesi Y, Semper H, Valent P, Niederberger V, Kraft D, Valenta R: Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003; 33: 1198-1208.
139. Drachenberg KJ, Wheeler AW, Stuebner P, Horak F: A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001; 56: 498-505.
140. Immunostimulatory DNA-Dynavax: AIC, Amb a 1 immunostimulatory conjugate, HBVISS, ISS 1018, ISS DNA, ISS DNA-Dynavax, ISS1, ISS2. Drugs R&D 2002; 3: 193-196.